‘Our goal is for Stevenage to emerge as a top destination for medical and scientific research by the end of the decade.’
GSK’s UK site could become one of Europe’s largest clusters for biotechnology and early-stage life science companies, with the company having revealed a plan to develop its R&D site in Stevenage, Hertfordshire. The company said that its plan aims to ‘unlock up to £400 million of new private investment and create up to 5000 new jobs.’
The plan for the new campus has been developed in partnership with Stevenage Bioscience Catalyst, the UK Government, Stevenage Borough Council and the Local Enterprise Partnership. GSK added that it had started the process of seeking a development partner to transform the land within the company’s Research & Development site. Work on planning the new site is slated to begin in 2022. It is hoped that the campus could attract world-class research organisations, creating opportunities for collaboration in life science. GSK’s site is already home to Cell and Gene Therapy Catapult and Stevenage Bioscience Catalyst.
Tony Wood, Senior Vice President Medicinal Science & Technology GSK said: ‘Our goal is for Stevenage to emerge as a top destination for medical and scientific research by the end of the decade.’
This development at GSK follows the recent announcement by the UK Government that it has launched a 10-year UK Life Sciences Vision for tackling some of the country’s biggest healthcare problems; including cancer and dementia. Sir Jonathan Symonds, Chairman, GSK, co-chaired the UK Life Sciences Vision’s External Advisory Board. The Board ensured that the breadth and depth of the sector were represented in the Vision’s development.